aren't MSB seeking approval from FDA with this?
Mesoblast Chief Medical Officer Dr Fred Grossman said: “We expect the mortality benefit observed in
this seminal Phase 3 trial will support a potential path for approval of rexlemestrocel-L in patients with
advanced chronic heart failure. We are planning to meet and discuss potential pathways to approval
based on mortality reduction with the United States Food and Drug Administration.”
aren't MSB seeking approval from FDA with this?Mesoblast Chief...
-
- There are more pages in this discussion • 857 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.5¢ |
Change
0.010(1.10%) |
Mkt cap ! $1.044B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 90.5¢ | $4.638M | 5.036M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 152669 | 91.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 51069 | 3 |
View Market Depth
| Last trade - 16.10pm 07/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |